These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1438625)

  • 21. Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures.
    Yao JK; van Kammen DP; Gurklis J
    Schizophr Res; 1994 Oct; 13(3):227-32. PubMed ID: 7841135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.
    Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D
    Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
    Yao JK; van Kammen DP
    Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.
    Viguera AC; Baldessarini RJ; Hegarty JD; van Kammen DP; Tohen M
    Arch Gen Psychiatry; 1997 Jan; 54(1):49-55. PubMed ID: 9006400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.
    Kramer MS; Vogel WH; DiJohnson C; Dewey DA; Sheves P; Cavicchia S; Little P; Schmidt R; Kimes I
    Arch Gen Psychiatry; 1989 Oct; 46(10):922-8. PubMed ID: 2679483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shifts in covert visual attention in schizophrenic patients and normal controls.
    Moran MJ; Thaker GK; Smith D; Cassady S; Layne-Gedge J
    Biol Psychiatry; 1992 Oct; 32(7):617-20. PubMed ID: 1450288
    [No Abstract]   [Full Text] [Related]  

  • 31. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
    Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
    Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine in tardive Tourette syndrome.
    Jaffe E; Trémeau F; Sharif Z; Reider R
    Biol Psychiatry; 1995 Aug; 38(3):196-7. PubMed ID: 7578666
    [No Abstract]   [Full Text] [Related]  

  • 34. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
    Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ
    Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia.
    Barbee JG; Mancuso DM; Freed CR; Todorov AA
    Am J Psychiatry; 1992 Apr; 149(4):506-10. PubMed ID: 1348161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial.
    Wilson WH
    Psychopharmacology (Berl); 1993; 111(3):359-66. PubMed ID: 7870975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skin conductance responding in schizophrenic patients with abnormal involuntary movements.
    Mintz M; Alfisi S; Sigal M
    Psychiatry Res; 1990 Oct; 34(1):19-27. PubMed ID: 1980017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Static and dynamic pupillometry for determination of the course of gradual detoxification of opiate-addicted patients.
    Grünberger J; Linzmayer L; Fodor G; Presslich O; Praitner M; Loimer N
    Eur Arch Psychiatry Clin Neurosci; 1990; 240(2):109-12. PubMed ID: 2149649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.